Syngeneic mouse model of epithelial ovarian cancer: Effects of nanoparticulate paclitaxel, nanotax®

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 169-181

  Roby, Katherine F ^a   Niu, Fenghui ^a   Rajewski, Roger A ^a   Decedue, Charles ^a   Subramaniam, Bala ^a   Terranova, Paul F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CREMOPHOR; ESTROGEN RECEPTOR ALPHA; NANOPARTICLE; NANOTAX; PACLITAXEL; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; EPITHELIUM CELL; ERYTHROCYTE AGGREGATION; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; MALIGNANT TRANSFORMATION; MOUSE; NANOPHARMACEUTICS; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYNGENEIC MODEL; TREATMENT OUTCOME;

EID: 84934436109     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_14     Document Type: Review

References (44)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. and Thun, M. (2006). "Cancer statistics, 2006." CA Cancer J Clin 56(2): 106-130.
2. Hogberg, T., Glimelius, B. and Nygren, P. (2001). "A systematic overview of chemotherapy effects in ovarian cancer." Acta Oncol 40(2-3): 340-360.
3. Connolly, D. C., Bao, R., Nikitin, A. Y., Stephens, K. C., Poole, T. W., Hua, X., Harris, S. S., Vanderhyden, B. C. and Hamilton, T. C. (2003). "Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer." Cancer Res 63(6): 1389-1397.
4. Yuspa, S. H. and Poirier, M. C. (1988). "Chemical carcinogenesis: from animal models to molecular models in one decade." Adv Cancer Res 50: 25-70.
5. Tunca, J. C., Erturk, E., Erturk, E. and Bryan, G. T. (1985). "Chemical induction of ovarian tumors in rats." Gynecol Oncol 21(1): 54-64.
6. Massazza, G., Tomasoni, A., Lucchini, V., Allavena, P., Erba, E., Colombo, N., Mantovani, A., D'Incalci, M., Mangioni, C. and Giavazzi, R. (1989). "Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy." Int J Cancer 44(3): 494-500.
7. Testa, J., Getts, L., Salazar, H., Liu, Z., Handel, L., Godwin, A. and Hamilton, T. (1994). "Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity." Cancer Res 54: 2778-2784.
8. Molpus, K. L., Kato, D., Hamblin, M. R., Lilge, L., Bamberg, M. and Hasan, T. (1996). "Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model." Cancer Res 56(6): 1075-1082.
9. Silva, E. G., Tornos, C., Deavers, M., Kaisman, K., Gray, K. and Gershenson, D. (1998). "Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation." Gynecol Oncol 71(2): 240-246.
10. Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G. and Terranova, P. F. (2000). "Development of a syngeniec mouse model for events related to ovarian cancer." Carcinogenesis 21(4): 585-591.
11. Selvakumaran, M., Bao, R., Crijns, A. P., Connolly, D. C., Weinstein, J. K. and Hamilton, T. C. (2001). "Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus- like element." Cancer Res 61(4): 1291-1295.
12. Orsulic, S., Li, Y., Soslow, R. A., Vitale-Cross, L. A., Gutkind, J. S. and Varmus, H. E. (2002). "Induction of ovarian cancer by defined multiple genetic changes in a mouse model system." Cancer Cell 1(1): 53-62.
13. Pieretti-Vanmarcke, R., Donahoe, P. K., Szotek, P., Manganaro, T., Lorenzen, M. K., Lorenzen, J., Connolly, D. C., Halpern, E. F. and MacLaughlin, D. T. (2006). "Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptordirected transgenic mouse ovarian cancers in vivo." Clin Cancer Res 12(5): 1593-1598.
14. Spencer, C. M. and Faulds, D. (1994). "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48(5): 794-784.
15. Gelderblom, H., Verweij, J., Nooter, K. and Sparreboom, A. (2001). "Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation." Eur J Cancer 37(13): 1590-1598.
16. Walter, K. A., Cahan, M. A., Gur, A., Tyler, B., Hilton, J., Colvin, O. M., Burger, P. C., Domb, A. and Brem, H. (1994). "Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma." Cancer Res 54(8): 2207-2212.
17. Sharma, A., Sharma, U. S. and Straubinger, R. M. (1996). "Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia." Cancer Lett 107(2): 265-272.
18. Harper, E., Dang, W., Lapidus, R. G. and Garver, R. I. J. (1999). "Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice." Clin Cancer Res 5(12): 4242-4248.
19. Leung, S. Y., Jackson, J., Miyake, H., Burt, H. and Gleave, M. E. (2000). "Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors." Prostate 44(2): 156-163.
20. Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J. and Beijnen, J. H. (2001). "Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel." Anticancer Drugs 12(4): 315-323.
21. Subramaniam, B., Rajewski, R. and Snavely, K. (1997). "Pharmaceutical processing with supercritical carbon dioxide." J Pharm Sci 86: 885-890.
22. Muhrer, G. and Mazzotti, M. (2003). "Precipitation of lysozyme nanoparticles from dimethyl sulfoxide using carbon dioxide as antisolvent." Biotechnol Prog 19(2): 549-556.
23. Perrut, M. (2003). "Supercritical fluids applications in the pharmaceutical industry." STP Pharma Sci 13(2): 83-91.
24. Subramaniam, B., Saim, S., Rajewski, R. and Stella, V. J. (Issued Nov. 10, 1998). Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents. US Patent 5,833,891.
25. Subramaniam, B., Bochniak, D. J. and Rajewski, R. (Issued Sept. 5, 2000). Methods for continuous particle precipitation and harvesting. U. S. Patent 6,113,795.
26. Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S. and Sickel, J. (2001). "Intraperitoneal drug delivery of antineoplastics." Drugs 61(8): 1057-1065.
27. Francis, P., Rowinsky, E., Schneider, J., Hakes, T., Hoskins, W. and Markman, M. (1995). "Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study." J Clin Oncol 13(12): 2961-2967.
28. Markman, M., Brady, M. F., Spirtos, N. M., Hanjani, P. and Rubin, S. C. (1998). "Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study." J Clin Oncol 16(8): 2620-2624.
29. Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L. J., Rubin, S., Curtin, J., Barakat, R. and Phillips, M. e. a. (1992). "Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study." J Clin Oncol 190(9): 1485-1491.
30. Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K. and DuBeshter, B. (1996). "Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus for stage III ovarian cancer." N Engl J Med 335(26): 1950-1955.
31. Vermorken, J. B. (2000). "The role of intraperitoneal chemotherapy in epithelial ovariancancer." Int J Gynecol Cancer 10(S1): 26-32.
32. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L. and Burger, R. A. (2006). "Intraperitoneal cisplatin and paclitaxel in ovarian cancer." N Engl J Med 354(1): 34-43.
33. Dyck, H., Hamilton, T., Godwin, A., Lynch, H., Maines-Bandiera, S. and Auersperg, N. (1996). "Autonomy of the epithelium phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer." Int J Cancer 69: 429-436.
34. Godwin, A., Testa, J., Handel, L., Liu, Z., Vanderveer, L., Tracey, P. and Hamilton, T. (1992). "Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer." J Natl Cancer Inst 84: 592-601.
35. Chen, X., Pine, P., Knapp, A., Tuse, D. and Laderoute, K. (1998). "Oncocidin A1: a novel tubulin-binding drug with antitumor activity against human breast and ovarian carcinoma xenographs in nude mice." Biochem Pharmacol 56(5): 623-633.
36. Mesiano, S., Ferrara, N. and Jaffe, R. (1998). "Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization." Am J Pathol 153(4): 1249-1256.
37. Stackhouse, M., Buchsbaum, D., Grizzle, W., Bright, S., Olsen, C., Kancharla, S., Mayo, M. and Curiel, D. (1998). "Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo." Int J Radiat Oncol Biol Phys 42(4): 817-822.
38. Fathalla, M. (1972). "Factors in the causation and incidence of ovarian cancer." Obstet Gynecol Surv 27: 751-768.
39. Parker, S., Tong, T., Bolden, S. and Wingo, P. (1996). "Cancer statistics 1996." CA Cancer J Clin 46: 5-27.
40. Kacinski, B. M. (1995). "CSF-1 and its receptor on ovarian, endometrial and breast cancer." Ann Med 27: 79-85.
41. Stack, M. S., Ellerbroek, S. M. and Fishman, D. A. (1998). "The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma." Int J Oncol 12(3): 569-576.
42. Bamberger, E. S. and Perrett, C. W. (2002). "Angiogenesis in epithelian ovarian cancer." Mol Pathol 2002 55(6): 348-359.
43. Cunat, S., Hoffmann, P. and Pujol, P. (2004). "Estrogens and epithelial ovarian cancer." Gynecol Oncol 94(1): 25-32.
44. Niu, F., Roby, K. F., Rajewski, R. A., Decedue, C. and Subramaniam, B. (2006). Paclitaxel Nanoparticles: Productrion using Compressed CO2 as Antisolvent, Characterization and Animal Model Studies. Polymeric Drug Delivery Volume II - Polymeric Matrices and Drug Particle Engineering. Svenson, S. Washington, DC, American Chemical Society. 924: 262-277.